"A pan-cancer and single-cell sequencing analysis of CD161, a promising onco-immunological biomarker in tumor microenvironment and immunotherapy"
作者全名:"Li, He; Zhou, Ke; Wang, Kaiyue; Cao, Hui; Wu, Wantao; Wang, Zeyu; Dai, Ziyu; Chen, Shi; Peng, Yun; Xiao, Gelei; Luo, Peng; Zhang, Jian; Liu, Zaoqu; Cheng, Quan; Zhang, Hao"
作者地址:"[Li, He; Wang, Kaiyue] Cent South Univ, Hunan Canc Hosp, Anim Lab Ctr, Changsha, Peoples R China; [Li, He; Wang, Kaiyue] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China; [Zhou, Ke; Chen, Shi] Hunan Normal Univ, Sch Med, Changsha, Peoples R China; [Wang, Kaiyue; Wang, Zeyu; Dai, Ziyu; Xiao, Gelei; Cheng, Quan] Cent South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Peoples R China; [Wang, Kaiyue; Wu, Wantao; Wang, Zeyu; Dai, Ziyu; Peng, Yun; Xiao, Gelei; Cheng, Quan] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Hunan, Peoples R China; [Cao, Hui] Second Peoples Hosp Hunan Prov, Brain Hosp Hunan Prov, Changsha, Peoples R China; [Cao, Hui] Hunan Univ Chinese Med, Sch Clin Med, Changsha, Peoples R China; [Wu, Wantao] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China; [Peng, Yun] Cent South Univ, Xiangya Hosp, Dept Geriatr, Changsha, Hunan, Peoples R China; [Peng, Yun] Cent South Univ, Xiangya Hosp, Teaching & Res Sect Clin Nursing, Changsha, Hunan, Peoples R China; [Luo, Peng; Zhang, Jian] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou, Peoples R China; [Liu, Zaoqu] First Affiliated Hosp Zhengzhou, Dept Intervent Radiol, Zhengzhou, Peoples R China; [Zhang, Hao] Chongqing Med Univ, Affiliated Hosp 2, Dept Neurosurg, Chongqing, Peoples R China"
通信作者:"Cheng, Q (通讯作者),Cent South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Peoples R China.; Cheng, Q (通讯作者),Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Hunan, Peoples R China.; Zhang, H (通讯作者),Chongqing Med Univ, Affiliated Hosp 2, Dept Neurosurg, Chongqing, Peoples R China."
来源:FRONTIERS IN IMMUNOLOGY
ESI学科分类:IMMUNOLOGY
WOS号:WOS:000913657200001
JCR分区:Q1
影响因子:7.3
年份:2022
卷号:13
期号:
开始页:
结束页:
文献类型:Article
关键词:CD161; prognosis; pan-cancer; mutation; macrophages; T cells; immunotherapy
摘要:"BackgroundCD161 has been linked to the appearance and development of various cancers. MethodsThe mutation map and the variation of CNVs and SNVs of CD161 were displayed according to cBioportal and GSCALite. We also evaluated the pathway enrichment and drug sensitivity of CD161 according to GSCALite. We performed a single-cell sequencing analysis of cancer cells and T cells in melanoma. The cell communication patterns related to CD161 were further explored. Multiplex immunofluorescence staining of tissue microarrays was used to detect the association between CD161 expression and macrophages and T cells. ResultsA high CD161 level was related to neoantigens expression, pathway enrichment, and drug sensitivity. In addition, single-cell sequencing analysis showed that CD161 was mainly expressed in T cells, M1 and M2 Macrophages, neoplastic, microglial cells, neurons, and cancer cells in many tumor types. Further study on pseudotime trajectories and functional annotation of CD161 proved the critical role of CD161 in tumor progression and T cell immunity in melanoma. Multiplex immunofluorescence revealed that CD161 is closely correlated with the immune infiltration of T cells and macrophages in multiple cancers. In addition, high CD161 expression predicted a favorable immunotherapy response. ConclusionCD161 is involved in the immune infiltration of T cells and macrophages and might be a promising target for tumor immunotherapy."
基金机构:
基金资助正文: